ArticleClinical and vaccine immunology : CVI2017
The Predominant CD4
Article in Clinical and vaccine immunology : CVI, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- Stimulated peripheral blood mononuclear cells from chlamydia-infected women release predominantly Th1-polarizing cytokines.Cytokine · 2019Trial
- Chlamydia trachomatis-specific T Cell Immunity Reflects Widespread Exposure in South African Adolescents and Young Women.The Journal of infectious diseases · 2026Article
- Evaluation of extracellular microRNAs as potential biomarker candidates for assessing chlamydia reinfection risk.PloS one · 2026Article
- Establishment and validation of red fox (vulpes vulpes) airway epithelial cell cultures at the air-liquid-interface.Scientific reports · 2025Article
- Low-Frequency, Sustained CD4 T-Cell Responses Chlamydia trachomatis in Women: Predominant Targeting of Chlamydial Proteaselike Activity Factor (CPAF).The Journal of infectious diseases · 2025Article
- Genome-wide association study of chlamydia reinfection in African American women.Frontiers in immunology · 2025Article
- Interferon-γ Responses to Chlamydia trachomatis Vaccine Candidate Proteins in Women With Different Chlamydia Outcomes.The Journal of infectious diseases · 2024Article
- Antibody responses toFrontiers in cellular and infection microbiology · 2024Article
- Insights into innate immune cell evasion byFrontiers in immunology · 2024Review
- Preparation of graphene oxide-stabilized Pickering emulsion adjuvant for Pgp3 recombinant vaccine and enhanced immunoprotection againstFrontiers in immunology · 2023Article
- Molecular Evaluation ofEthiopian journal of health sciences · 2021Article
- Vaccines: Underlying Principles of Design and Testing.Clinical pharmacology and therapeutics · 2021Article
- [Role of tumor necrosis factor-α inNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020Article
- Impact of Helminth Infections on Female Reproductive Health and Associated Diseases.Frontiers in immunology · 2020Review
- Antigen-specific memory and naïve CD4+ T cells following secondary Chlamydia trachomatis infection.PloS one · 2020Article
- Mycoplasma genitalium Coinfection in Women With Chlamydia trachomatis Infection.Sexually transmitted diseases · 2019Article
- High expression of IDO1 and TGF-β1 during recurrence and post infection clearance with Chlamydia trachomatis, are independent of host IFN-γ response.BMC infectious diseases · 2019Article
- T cell phenotypes in women with Chlamydia trachomatis infection and influence of treatment on phenotype distributions.Microbes and infection · 2018Article
- An AdaptiveFrontiers in immunology · 2018Article
- TheFrontiers in immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.